Literature DB >> 2874500

Modulation by fenoldopam (SKF 82526) and bromocriptine of the electrically evoked release of vasopressin from the rat neurohypophysis. Effects of dopamine depletion.

K Racké, J Meuresch, B Trapp, E Muscholl.   

Abstract

Single neurointermediate lobes were fixed by their stalks to a platinum wire electrode and incubated in Krebs-bicarbonate solution. Vasopressin release into the medium was determined by a radioimmunoassay. Vasopressin secretion was increased by electrical stimulation (15 Hz, 10 s trains with 10 s intervals for 10 min). Fenoldopam (SKF 82526) had a dual effect on vasopressin release, 30 nM decreasing (by 30%) and 3 microM increasing (by 32%) the evoked vasopressin secretion. The facilitatory effect of fenoldopam was antagonized in a concentration-dependent manner by flupenthixol but not by sulpiride. Sulpiride (1 microM) prevented the inhibitory effect of fenoldopam (30 microM). After pretreatment of the rats with the dopamine depleting agent, Ro4-1284 (2 mg/kg i.p. 1 h before the experiments), the evoked vasopressin release was decreased by 21% and the inhibitory effect of fenoldopam disappeared, but the facilitatory effect of fenoldopam was already seen at 30 nM. Similarly, bromocriptine (1-10 microM) decreased the evoked vasopressin release from untreated neurointermediate lobes by 30-40% but increased the vasopressin release by 30% after pretreatment with Ro4-1284. The present findings further support the concept that vasopressin from the neurohypophysis is modulated by dopaminergic mechanisms. Facilitatory effects are mediated via D 1 and inhibition via D 2 receptors. The presence of endogenous dopamine seems to be necessary for the inhibitory effects to occur.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874500     DOI: 10.1007/bf00500083

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors.

Authors:  D R Sibley; S E Leff; I Creese
Journal:  Life Sci       Date:  1982-08-16       Impact factor: 5.037

3.  Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.

Authors:  K Fuxe; B B Fredholm; L F Agnati; S O Ogren; B J Everitt; G Jonsson; J A Gustafsson
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

4.  Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro.

Authors:  K Starke; W Reimann; A Zumstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

5.  Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.

Authors:  J Weinstock; J W Wilson; D L Ladd; C K Brush; F R Pfeiffer; G Y Kuo; K G Holden; N C Yim; R A Hahn; J R Wardell; A J Tobia; P E Setler; H M Sarau; P T Ridley
Journal:  J Med Chem       Date:  1980-09       Impact factor: 7.446

6.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

Authors:  R A Hahn; J R Wardell; H M Sarau; P T Ridley
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

7.  Effects of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation.

Authors:  D C German; B A McMillen; M K Sanghera; S I Saffer; P A Shore
Journal:  Brain Res Bull       Date:  1981-02       Impact factor: 4.077

8.  Release of endogenous 3,4-dihydroxyphenylethylamine and its metabolites from the isolated neurointermediate lobe of the rat pituitary gland. Effects of electrical stimulation and of inhibition of monoamine oxidase and reuptake.

Authors:  K Racké; E Muscholl
Journal:  J Neurochem       Date:  1986-03       Impact factor: 5.372

9.  Forskolin: its effects on potassium-evoked release of vasopressin from the rat neurohypophysis.

Authors:  D Bowman; D B Hope
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

10.  Dopamine and [D-ALA2, D-Leu5]enkephalin inhibit the electrically stimulated neurohypophyseal release of vasopressin in vitro: evidence for calcium-dependent opiate action.

Authors:  S L Lightman; L L Iversen; M L Forsling
Journal:  J Neurosci       Date:  1982-01       Impact factor: 6.167

View more
  3 in total

1.  Presynaptic regulation of the electrically evoked release of endogenous dopamine from the isolated neurointermediate lobe or isolated neural lobe of the rat pituitary gland in vitro.

Authors:  K Racké; A Grosshans; S Sirrenberg; K Ziegler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

2.  Dopamine D2 receptor activation depolarizes rat supraoptic neurones in hypothalamic explants.

Authors:  C R Yang; C W Bourque; L P Renaud
Journal:  J Physiol       Date:  1991-11       Impact factor: 5.182

3.  Effect of dopamine antagonists on the urine flow of rats infused with hypotonic saline.

Authors:  P Angchanpen; M Marin-Grez; J Schnermann
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.